Plant ID: NPO12895
Plant Latin Name: Polypodiodes niponica
Taxonomy Genus: Polypodiodes
Taxonomy Family: Polypodiaceae
NCBI TaxonomyDB:
126675
Plant-of-the-World-Online:
n.a.
TSHR; | |
PPARD; PPARA; | |
TLR2; | |
TP53; | |
FABP3; FABP5; FABP2; FABP4; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.084E-09 | 3.532E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 1.548E-09 | 4.213E-06 | FABP2, FABP3, FABP4, FABP5 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.809E-08 | 2.462E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.850E-08 | 3.387E-05 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.145E-07 | 2.446E-04 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 4.185E-07 | 2.848E-04 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 4.916E-07 | 3.056E-04 | CYP1A1, PPARA, PPARD, TLR2, TP53 |
MF | GO:0005488; binding | GO:0020037; heme binding | 1.256E-06 | 6.077E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.507E-06 | 1.092E-03 | CYP1A1, CYP1A2 |
BP | GO:0032502; developmental process | GO:0048856; anatomical structure development | 2.868E-06 | 1.178E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, FABP5, PPARA, PPARD, TLR2, TP53, TSHR |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.059E-06 | 1.233E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0005488; binding | GO:0097371; MDM2/MDM4 family protein binding | 8.764E-06 | 3.078E-03 | PPARA, TP53 |
BP | GO:0051179; localization | GO:0015908; fatty acid transport | 1.113E-05 | 3.786E-03 | FABP3, PPARA, PPARD |
BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 1.168E-05 | 3.913E-03 | CYP1A1, CYP1A2 |
BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 1.693E-05 | 5.584E-03 | PPARA, PPARD, TP53 |
BP | GO:0008152; metabolic process | GO:1902894; negative regulation of pri-miRNA transcription from RNA polymerase II promoter | 2.292E-05 | 7.129E-03 | PPARA, PPARD |
MF | GO:0005488; binding | GO:0036041; long-chain fatty acid binding | 2.292E-05 | 7.129E-03 | FABP3, PPARD |
BP | GO:0008152; metabolic process | GO:0001523; retinoid metabolic process | 2.705E-05 | 8.196E-03 | CYP1A1, CYP1B1, PPARD |
BP | GO:0009987; cellular process | GO:0071280; cellular response to copper ion | 3.248E-05 | 9.688E-03 | CYP1A1, CYP1A2 |
BP | GO:0051704; multi-organism process | GO:0002237; response to molecule of bacterial origin | 3.464E-05 | 9.926E-03 | CYP1A1, CYP1A2, PPARD, TLR2 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 2.273E-12 | 1.568E-10 | FABP2, FABP3, FABP4, FABP5, PPARA, PPARD |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 4.464E-08 | 1.540E-06 | CYP1A2, CYP1A1, CYP1B1, CYP19A1 |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 2.090E-06 | 4.808E-05 | CYP1A2, CYP1A1, CYP1B1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 4.131E-06 | 7.127E-05 | CYP1A1, CYP1B1, CYP19A1 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.300E-05 | 1.794E-04 | CYP1A2, CYP1A1, CYP1B1 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.844E-05 | 2.121E-04 | CYP1A2, CYP1A1, CYP1B1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 5.889E-04 | 5.804E-03 | FABP4, TSHR |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 7.927E-04 | 6.837E-03 | CYP1A2, CYP1A1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 3.263E-03 | 2.079E-02 | PPARA, TP53 |
09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 3.246E-03 | 2.079E-02 | CYP1A2 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; |
C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |